Effects of the C5aR1 blockade, Poly I:C and anti/PD1 combined treatment in the gene expression in LLC tumors
RNA-seq (gene expression) · mouse · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 24 samples: 8 × C and anti-PD vs 8 × C, anti-PD-1 and anti-C5aGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE239485_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA999384 and SRA study SRP451881. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 16 samples.
How we read this: 2 replicated groups read from 24 sample titles; they account for 16 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7666074 C_339_S25, Control vehicle
- GSM7666075 C_351_S29, Control vehicle
- GSM7666076 C_356_S27, Control vehicle
- GSM7666077 C_358_S26,Control vehicle
- GSM7666078 C_361_S32, Control vehicle
- GSM7666079 C_364_S28, Control vehicle
- GSM7666080 C_369_S30, Control vehicle
- GSM7666081 C_375_S31, Control vehicle
- GSM7666082 D_344_S33, Poly I:C and anti-PD-1 C and anti-PD
- GSM7666083 D_357_S37, Poly I:C and anti-PD-1 C and anti-PD
- GSM7666084 D_359_S39, Poly I:C and anti-PD-1 C and anti-PD
- GSM7666085 D_366_S34, Poly I:C and anti-PD-1 C and anti-PD
- GSM7666086 D_367_S35, Poly I:C and anti-PD-1 C and anti-PD
- GSM7666087 D_368_S36, Poly I:C and anti-PD-1 C and anti-PD
- GSM7666088 D_370_S38, Poly I:C and anti-PD-1 C and anti-PD
- GSM7666089 D_373_S40, Poly I:C and anti-PD-1 C and anti-PD
- GSM7666090 T_331_S44, Poly I:C, anti-PD-1 and anti-C5aR1 C, anti-PD-1 and anti-…
- GSM7666091 T_352_S48, Poly I:C, anti-PD-1 and anti-C5aR1 C, anti-PD-1 and anti-…
- GSM7666092 T_353_S45, Poly I:C, anti-PD-1 and anti-C5aR1 C, anti-PD-1 and anti-…
- GSM7666093 T_354_S47, Poly I:C, anti-PD-1 and anti-C5aR1 C, anti-PD-1 and anti-…
- GSM7666094 T_355_S43, Poly I:C, anti-PD-1 and anti-C5aR1 C, anti-PD-1 and anti-…
- GSM7666095 T_360_S46, Poly I:C, anti-PD-1 and anti-C5aR1 C, anti-PD-1 and anti-…
- GSM7666096 T_362_S42, Poly I:C, anti-PD-1 and anti-C5aR1 C, anti-PD-1 and anti-…
- GSM7666097 T_363_S41, Poly I:C, anti-PD-1 and anti-C5aR1 C, anti-PD-1 and anti-…
- GSE311831 Pertussis toxin-induced lymphocytosis enhances anti-tumor immune environments and improves the anti-PD1 treatment response in a squamous cell carcinoma model. 24 samples shares pd1, treatment, anti
- GSE280861 Combined blockade of CXCR4 and PD1 enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma 10 samples shares pd1, blockade, combined
- GSE248155 Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma 31 samples shares pd1, anti
- GSE272309 Investigate the role of B cell in response to anti-PD1 + anti-CTLA in hepatocellular carcinoma 21 samples shares pd1, anti
- GSE248154 Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [4NQO_model] 19 samples shares pd1, anti
- GSE250165 PD1 blockade improves survival and CD8+ cytotoxic capacity, without increasing inflammation, during normal microbial experience in old mice 14 samples shares pd1, blockade
- GSE248153 Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [HNSCC_model] 12 samples shares pd1, anti
- GSE304155 HE4 regulates anticancer immune evasion by upregulating PD-L1 expression on macrophages through the IFN-γR-STAT3 axis [LLC tumors, scRNA-seq] 6 samples shares llc, anti
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.